A5068642524- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- Lung Cancer Treatments and Mutations
- Cancer therapeutics and mechanisms
- RNA Interference and Gene Delivery
- HIV/AIDS drug development and treatment
- Multiple Myeloma Research and Treatments
- CRISPR and Genetic Engineering
- Lung Cancer Research Studies
- Insect Resistance and Genetics
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Neuroendocrine Tumor Research Advances
- PI3K/AKT/mTOR signaling in cancer
- Eosinophilic Disorders and Syndromes
Oregon Health & Science University
2019-2025
OHSU Knight Cancer Institute
2020
Cancer Institute (WIA)
2020
Abstract The BCL2 inhibitor venetoclax combined with the hypomethylating agent azacytidine shows significant clinical benefit in a subset of patients acute myeloid leukemia (AML); however, resistance limits response and durability. We prospectively profiled ex vivo activity 25 venetoclax-inclusive combinations on primary AML patient samples to identify those improved potency synergy compared + (Ven azacytidine). Combination sensitivities correlated tumor cell state discern three patterns:...
Not available.
<p>Novel VEN combo partner drugs, targets, and status</p>
<p>Comparison of feature balance between training and test cohorts</p>
<p>Correlations of cell state gene sig with drug sensitivity</p>
<div>Abstract<p>The BCL2 inhibitor venetoclax combined with the hypomethylating agent azacytidine shows significant clinical benefit in a subset of patients acute myeloid leukemia (AML); however, resistance limits response and durability. We prospectively profiled <i>ex vivo</i> activity 25 venetoclax-inclusive combinations on primary AML patient samples to identify those improved potency synergy compared + (Ven azacytidine). Combination sensitivities correlated tumor...
<p>Validation target sgRNA and TIDE primer reagent sequences</p>
<p>Novel VEN combo partner drugs, targets, and status</p>
<p>Ridge regression coefficients</p>
<p>Sensitivity of OCI-AML2 CRISPR/Cas9-KO cell line models to venetoclax or the MDM2 antagonist idasanutlin</p>
<p>Sensitivity and synergy of the Ven+Ruxolitinib combination in AML cell lines</p>
<p>Pairwise feature KW test screen</p>
<p>Ridge regression coefficients</p>
<p>Full ex vivo AUC values and clinical annotations</p>
<p>Cell line DE genes for VEN+Ruxolitinib</p>
<p>Full ex vivo AUC values and clinical annotations</p>
<p>Pairwise feature KW test screen</p>
<p>Cell line DE genes for VEN+Ruxolitinib</p>
<p>Screening of venetoclax combinations and respective single agents against non-leukemic human stromal bone marrow mononuclear cells</p>
<p>Validation target sgRNA and TIDE primer reagent sequences</p>